227 related articles for article (PubMed ID: 17683996)
1. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.
Abitbol V; Briot K; Roux C; Roy C; Seksik P; Charachon A; Bouhnik Y; Coffin B; Allez M; Lamarque D; Chaussade S
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1184-9. PubMed ID: 17683996
[TBL] [Abstract][Full Text] [Related]
2. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients.
Herrala J; Puolijoki H; Liippo K; Raitio M; Impivaara O; Tala E; Nieminen MM
Bone; 1998 May; 22(5):577-82. PubMed ID: 9600795
[TBL] [Abstract][Full Text] [Related]
3. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW
Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
[TBL] [Abstract][Full Text] [Related]
4. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
[TBL] [Abstract][Full Text] [Related]
5. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.
Heikkinen JE; Selander KS; Laitinen K; Arnala I; Väänänen HK
J Bone Miner Res; 1997 Jan; 12(1):103-10. PubMed ID: 9240732
[TBL] [Abstract][Full Text] [Related]
6. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
Tee SI; Yosipovitch G; Chan YC; Chua SH; Koh ET; Chan YH; Tan SS; Tsou IY; Tan SH
Arch Dermatol; 2012 Mar; 148(3):307-14. PubMed ID: 22105813
[TBL] [Abstract][Full Text] [Related]
7. A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial.
Klaus J; Haenle MM; Schröter C; Adler G; von Boyen G; Reinshagen M; von Tirpitz C
Am J Gastroenterol; 2011 Apr; 106(4):786-93. PubMed ID: 21386830
[TBL] [Abstract][Full Text] [Related]
8. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound.
Frediani B; Falsetti P; Baldi F; Acciai C; Filippou G; Marcolongo R
Bone; 2003 Oct; 33(4):575-81. PubMed ID: 14555261
[TBL] [Abstract][Full Text] [Related]
9. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women.
Tsai KS; Hsu SH; Yang RS; Cheng WC; Chieng PU
Calcif Tissue Int; 1999 May; 64(5):384-8. PubMed ID: 10203414
[TBL] [Abstract][Full Text] [Related]
11. "Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
Muratore M; Quarta L; Calcagnile F; Quarta E
Adv Ther; 2010 May; 27(5):314-20. PubMed ID: 20526703
[TBL] [Abstract][Full Text] [Related]
12. Improved efficacy of intramuscular weekly administration of clodronate 200 mg (100 mg twice weekly) compared with 100 mg (once weekly) for increasing bone mineral density in postmenopausal osteoporosis.
Frediani B; Bertoldi I; Pierguidi S; Nicosia A; Picerno V; Filippou G; Cantarini L; Galeazzi M
Clin Drug Investig; 2013 Mar; 33(3):193-8. PubMed ID: 23456672
[TBL] [Abstract][Full Text] [Related]
13. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.
Henderson S; Hoffman N; Prince R
Am J Gastroenterol; 2006 Jan; 101(1):119-23. PubMed ID: 16405543
[TBL] [Abstract][Full Text] [Related]
14. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
Mok CC; Ying KY; To CH; Ho LY; Yu KL; Lee HK; Ma KM
Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with an immunomodulator and anti-TNFα agent improves bone mineral density in IBD patients.
Krajcovicova A; Hlavaty T; Killinger Z; Miznerova E; Toth J; Letkovsky J; Nevidanska M; Cierny D; Koller T; Zelinkova Z; Huorka M; Payer J
J Crohns Colitis; 2014 Dec; 8(12):1693-701. PubMed ID: 25175812
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
[TBL] [Abstract][Full Text] [Related]
18. Effect of bisphosphonates on bone mineral density and fracture prevention in gastric cancer patients after gastrectomy.
Lim JS; Jin SH; Kim SB; Lee JI
J Clin Gastroenterol; 2012 Sep; 46(8):669-74. PubMed ID: 22504799
[TBL] [Abstract][Full Text] [Related]
19. Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition.
Haderslev KV; Tjellesen L; Sorensen HA; Staun M
Am J Clin Nutr; 2002 Aug; 76(2):482-8. PubMed ID: 12145026
[TBL] [Abstract][Full Text] [Related]
20. Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease.
Kriel MH; Tobias JH; Creed TJ; Lockett M; Linehan J; Bell A; Przemioslo R; Smithson JE; Brooklyn TN; Fraser WD; Probert CS
Osteoporos Int; 2010 Mar; 21(3):507-13. PubMed ID: 19484170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]